Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase

US7935725B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Scott D. Bembenek · San Diego, US
• Wendy Eccles · San Diego, US
• Laurent Gomez · San Diego, US
• Cheryl A. Grice · Carlsbad, US
• Aaron M. Kearney · Lakeside, US
• Adrienne M. Landry-Bayle · Carlsbad, US
• Taraneh Mirzadegan · San Diego, US
• Alejandro Santillán, Jr. · San Diego, US

Key dates

• Filing date: Oct 30, 2008
• Grant date: May 3, 2011
• Expiry date: Nov 30, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.